← Therapy pipeline
Investigational · Obesity development

Macupatide

LY3532226 · Eli Lilly

A long-acting GIP receptor agonist studied alone and with eloralintide.

GIP
Other study areas
Type 2 diabetes
Selected program areas, not approvals. See the full profile for individual trials.
Obesity stagePhase 2Updated as of November 2026
SponsorEli Lilly
TargetsGIP
RouteInjection
DevelopmentObesity-specific
01 / Evidence

Results availability

No numerical results shown

No numerical study results are currently summarized for this profile. The development stage and linked studies are listed below.

02 / How it works

Mechanism at a glance

GLP-1GLP-1—
GIPGIPTargeted
GCGglucagon—
AMYamylin—
OTHOther targets—
Explore the hormone anatomy ↗
03 / Development

Obesity stage by formulation

InjectionOnce weekly
Phase 2Phase 2 obesity studies include participants with and without type 2 diabetes
Milestone → next

Latest: Lilly lists Phase 2 weight-management studies in adults with and without type 2 diabetes; the no-diabetes study is Phase 2b.

Next: Results and Lilly’s next-step development plans.

04 / Study records

Clinical study records

Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.

Obesity and weight-management studies

Phase 2 studies1 record

Phase 2b

NCT07589608 · obesity without type 2 diabetes

Weight management without type 2 diabetes
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Master-protocol study testing macupatide and eloralintide alone or in combination in adults with obesity or overweight without type 2 diabetes.

Related conditions and outcomes

Phase 2 studies1 record

Phase 2

NCT07215559 · obesity with type 2 diabetes

Glycemic control in type 2 diabetes
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Study of macupatide and eloralintide alone or in combination in adults with obesity or overweight and type 2 diabetes.